These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19395691)

  • 1. Optimal dosing and dynamic distribution of vaccines in an influenza pandemic.
    Wood J; McCaw J; Becker N; Nolan T; MacIntyre CR
    Am J Epidemiol; 2009 Jun; 169(12):1517-24. PubMed ID: 19395691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving seasonal and pandemic influenza vaccines.
    Saville M; Marsh G; Hoffenbach A
    Influenza Other Respir Viruses; 2008 Nov; 2(6):229-35. PubMed ID: 19453399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple mathematical approach to deciding the dosage of vaccine against pandemic H1N1 influenza.
    Nishiura H; Iwata K
    Euro Surveill; 2009 Nov; 14(45):. PubMed ID: 19941790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate.
    Riley S; Wu JT; Leung GM
    PLoS Med; 2007 Jun; 4(6):e218. PubMed ID: 17579511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine supply: building long-term sustainability.
    Hehme N; Colegate T; Palache B; Hessel L
    Vaccine; 2008 Sep; 26 Suppl 4():D23-6. PubMed ID: 19230154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza update 2007-2008: vaccine advances, pandemic preparation.
    Mossad SB
    Cleve Clin J Med; 2007 Dec; 74(12):889-94. PubMed ID: 18183839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.
    Kreijtz JH; Osterhaus AD; Rimmelzwaan GF
    Hum Vaccin; 2009 Mar; 5(3):126-35. PubMed ID: 18948744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
    Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
    Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
    Reed C; Meltzer MI; Finelli L; Fiore A
    Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
    Onishchenko GG; Zverev VV; Katlinskiĭ AV; Semchenko AV; Korovkin SA; Mel'nikov SIa; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):15-9. PubMed ID: 17882832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal control of vaccination dynamics during an influenza epidemic.
    Jaberi-Douraki M; Moghadas SM
    Math Biosci Eng; 2014 Oct; 11(5):1045-63. PubMed ID: 25347806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survey of vaccine distribution and delivery issues in the USA: from pediatrics to pandemics.
    Jacobson SH; Sewell EC; Jokela JA
    Expert Rev Vaccines; 2007 Dec; 6(6):981-90. PubMed ID: 18377360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the potential effects of a vaccine program against an emerging influenza pandemic--United States.
    Biggerstaff M; Reed C; Swerdlow DL; Gambhir M; Graitcer S; Finelli L; Borse RH; Rasmussen SA; Meltzer MI; Bridges CB
    Clin Infect Dis; 2015 May; 60 Suppl 1(Suppl 1):S20-9. PubMed ID: 25878298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the role of basic control measures, antivirals and vaccine in curtailing pandemic influenza: scenarios for the US, UK and the Netherlands.
    Nuño M; Chowell G; Gumel AB
    J R Soc Interface; 2007 Jun; 4(14):505-21. PubMed ID: 17251132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing influenza vaccine distribution.
    Medlock J; Galvani AP
    Science; 2009 Sep; 325(5948):1705-8. PubMed ID: 19696313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
    Fiore AE; Uyeki TM; Broder K; Finelli L; Euler GL; Singleton JA; Iskander JK; Wortley PM; Shay DK; Bresee JS; Cox NJ;
    MMWR Recomm Rep; 2010 Aug; 59(RR-8):1-62. PubMed ID: 20689501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges.
    Hessel L;
    Influenza Other Respir Viruses; 2009 Jul; 3(4):165-70. PubMed ID: 19627373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.